PHARMACEUTICAL IP

  • Offering
    • Evolve AI
      • Albert
        • Validity analysis
        • Albert Construe
      • Popper
      • Franklin
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert
      • Validity analysis
      • Albert Construe
    • Popper
    • Franklin
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
    • Evolve AI
      • Albert
        • Validity analysis
        • Albert Construe
      • Popper
      • Franklin
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert
      • Validity analysis
      • Albert Construe
    • Popper
    • Franklin
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team

Podcast: Staring into the AI abyss

  • Technology: Patent law
  • 14th July 2026
INSIGHT epi - The podcast for European patent professionals
Ordered block of gold plates with three turquoise plates lifted out on dark blue, Evolve abstract article image

In this episode of the INSIGHT epi – The podcast for European patent professionals, Bastian Best and Evolve’s Rose Hughes discuss the impact of artificial intelligence on the patent profession. They explore whether AI represents an existential threat or simply another technological shift, separating legal-tech hype from reality and examining where today’s AI tools genuinely add value – and where they still fall short. They also consider what these developments mean for the future role of patent attorneys and how the profession is likely to evolve in the years ahead.

Evolve AI

Listen to the podcast here.

Related insights...

Twisting strand of gold beads with a turquoise section on dark blue, Evolve biotechnology image
Twisting strand of gold beads with a turquoise section on dark blue, Evolve biotechnology image

AI for patent sequences: Avoiding costly sequence errors

  • 6th November 2026
A single wrong residue can mean a patent does not cover the product. Evolve’s AI Sequence Agents build ST.26 listings in code, check every residue, keep the claims covering the lead in line with the IP strategy from drafting to grant, and check the sequences in granted patents.
Grid of gold cubes with one turquoise cube lifted on dark blue, Evolve AI drug discovery image
Grid of gold cubes with one turquoise cube lifted on dark blue, Evolve AI drug discovery image

AI in the patent industry: Instant coffee Copilot

  • 4th November 2026
It is now abundantly clear that AI cannot be ignored by the patent industry. However, amongst the private practice firms, there still remains a divergence of approach, with many attorneys still not using AI in their day-to-day practice.
Ordered block of gold plates with three turquoise plates lifted out on dark blue, Evolve abstract article image
Ordered block of gold plates with three turquoise plates lifted out on dark blue, Evolve abstract article image

AI in the patent industry: The sneaky practice of prompt injection (and what to do about it)

  • 30th October 2026
As patent attorneys, we are by now all hopefully well versed in the confidentiality and hallucination risks of using AI. However, as AI tools are increasingly used to read, summarise and come to conclusions about third-party documents, there is another risk we need to think about: prompt injection. This is the sneaky practice of hiding…
Pyramid of gold spheres with a turquoise apex and pink equator line on dark blue, Evolve Franklin image
Pyramid of gold spheres with a turquoise apex and pink equator line on dark blue, Evolve Franklin image

Franklin: AI-powered publication review for pharma

  • 23rd October 2026
Publication screening is a time sink for pharma patent attorneys. Franklin quickly finds the undisclosed inventions in a new publication submission.
Turquoise sphere held in gold gyroscope rings with a pink edge line on dark blue, Evolve Albert image
Turquoise sphere held in gold gyroscope rings with a pink edge line on dark blue, Evolve Albert image

Albert – Construe: defining your claims before they are defined for you.

  • 25th September 2026
Albert – Construe is the latest addition to Evolve’s proprietary AI toolkit.  It construes a set of claims, sets out with supporting evidence what each unclear term means, highlights any inconsistencies caused by other disclosures within an application, and flags where amendments may have changed the scope of a claim term.
Ordered block of gold plates with three turquoise plates lifted out on dark blue, Evolve abstract article image
Ordered block of gold plates with three turquoise plates lifted out on dark blue, Evolve abstract article image

AI in the patent industry: Beware the MCP Trojan horse

  • 11th September 2026
As patent attorneys, we should all know by now not to put client confidential information into a non-enterprise version of an LLM. However, as the capabilities of AI tools become more complex, so too does the necessity of understanding what exactly they are doing and where our data goes, beyond the simple prompt.
Gold bar dissolving into turquoise fragments at its centre on dark blue, Evolve abstract article image
Gold bar dissolving into turquoise fragments at its centre on dark blue, Evolve abstract article image

AI in the patent industry: Bubble trouble and the affordability myth

  • 20th July 2026
Whenever we write about AI, responses have started to move away from talk about hallucination, confidentiality or quality. The new concern is one of economics, i.e. will the whole AI thing just become too expensive and are we putting ourselves at risk by outsourcing to AI.
Gold band splitting into three branches at a turquoise junction on dark blue, Evolve abstract article image
Gold band splitting into three branches at a turquoise junction on dark blue, Evolve abstract article image

AI in the patent industry: The risks of AI shadow use

  • 8th July 2026
In many patent firms, permission to use AI tools is currently restricted to the most senior individuals. Whilst almost every firm seems to have a dedicated “AI task-force” these days to trial new software, this group is usually restricted to partners or senior associates, whilst trainees and more junior associates are denied access to AI…
Turquoise sphere held in gold gyroscope rings with a pink edge line on dark blue, Evolve Albert image
Turquoise sphere held in gold gyroscope rings with a pink edge line on dark blue, Evolve Albert image

Albert: AI-powered competitive intelligence and IP validity analysis for biotech & pharma

  • 23rd June 2026
Expert analysis based on deep industry expertise, delivered quickly and cost-effectively.
Swarm of gold spheres with one large turquoise sphere at the centre on dark blue, Evolve abstract article image
Swarm of gold spheres with one large turquoise sphere at the centre on dark blue, Evolve abstract article image

AI in the patent industry: Don’t believe the hype. Believe the data.

  • 9th June 2026
Many in the IP profession remain considerably sceptical of AI. AI may be useful for checking for typos and simple calculations of deadlines, but it cannot replace in-depth human reasoning about complex scientific and legal issues. However, the data suggests something different.
All Insights

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2026 All Rights Reserved

Keep in touch

  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice
  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice